SCHEMBL4939866

SCHEMBL4939866

CC(=O)Nc1n[nH]c2nc(-c3ccccc3O)cc(C3CCCN(C(=O)O)C3)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 6/20 0.50
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RAC1 P63000 1/20 0.38
ADORA2A P29274 1/20 0.38
BRS3 P32247 1/20 0.37
BTK Q06187 2/20 0.37
SCN9A Q15858 1/20 0.36
AXL P30530 1/20 0.36
MAPK1 P28482 1/20 0.36
GAA P10253 1/20 0.36
MYC P01106 1/20 0.35
PDE2A O00408 1/20 0.35
CHUK O15111 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148227 0.86 IKBKB (0.41) IKBKBGSK3AGSK3BCYP1A2CYP3A4
SCHEMBL14028470 0.84 IKBKB (0.70) IKBKBGSK3AGSK3BADORA2ACHUK
Hydrochloric Acid SCHEMBL4945343 0.83 IKBKB (0.69) IKBKBGSK3AGSK3BADORA2ACHUK
SCHEMBL4946214 0.82 IKBKB (0.71) IKBKBGAACHUK
SCHEMBL14028460 0.78 PRMT5 (0.47)
SCHEMBL4947306 0.76 SMARCA2 (0.49) IKBKBBTKCHUK
SCHEMBL4942772 0.75 IKBKB (0.56) IKBKBSCN9AMYCPDE2ACHUK
SCHEMBL5256948 0.73 BTK (0.42) IKBKBCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4942229 0.72 IKBKB (0.53) IKBKBSCN9AMYCPDE2ACHUK
SCHEMBL4945716 0.72 IKBKB (0.52) IKBKBMYCPDE2ACHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7435743-B2 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2008-10-14 US disclosed
EP-1326856-B1 PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY BAYER HEALTHCARE AG (DE) 2007-12-19 EP disclosed
US-7232909-B2 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2007-06-19 US disclosed
US-20060205676-A1 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2006-09-14 US disclosed
US-20060100246-A1 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2006-05-11 US disclosed
US-6984649-B1 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2006-01-10 US disclosed
US-6562811-B1 Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation BAYER AKTIENGESELLSCHAFT (DE) 2003-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205676-A1 Pyridine derivatives CBR3, ARG1, HRH3 IKBKB 1024/4885GSK3A 4776/4885GSK3B 4644/4885
US-20060100246-A1 Pyridine derivatives NAPRT, NNT, NANS IKBKB 2996/4885GSK3A 3699/4885GSK3B 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.